Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Pain is common in cancer patients, particularly in the advanced stage of disease when the prevalence is estimated to be more than 70% [1], contributing to poor physical and emotional well-being. The most comprehensive systematic review indicates pain prevalence ranging from 33% in patients after curative treatment, to 59% in patients on anticancer treatment and to 64% in patients with metastatic, advanced or terminal disease [2]. Pain has a high prevalence earlier in disease in specific cancer types such as pancreatic (44%) and head and neck cancer (40%) [3].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 2 The assessment of BTcP. BTcP, breakthrough cancer pain. Reprinted with permission from [116].](https://figures.cochat.ai/paper-figures/ca72788a69f549f1926fbf99429f0118/management-of-cancer-pain-in-adult-patients-esmo-clinical-practice-guidelines-figure-2.png)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the recent ESMO guidelines106 are difficult to follow in those countries where the majority of patients experiencing cancer pain live.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [106]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Pain and Its Treatment in Outpatients with Metastatic Cancer
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A., & Pandya, K. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300902 · Cited by 2,019
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
van den Beuken-van Everdingen, M. H. J., de Rijke, J. M., Kessels, A. G., Schouten, H. C., van Kleef, M., & Patijn, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm056 · Cited by 1,923
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70040-2 · Cited by 1,243
Self-citation
Cited by
Items 201–300 of 954
Løhre, E. T., Thronæs, M., Brunelli, C., Kaasa, S., & Klepstad, P. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04836-8 · Cited by 12
A Review on the Management of Symptoms in Patients with Incurable Cancer
Gonçalves, F., Gaudêncio, M., Rocha, A. M. D. N., Paiva, I., Rêgo, F. M. P. D. S., & Nunes, R. (2025) · Current Oncology · doi:10.3390/curroncol32080433 · Cited by 19
Peripheral nerve blocks in advanced cancer pain: retrospective case series
Rouhento, E. A. S., Lehto, J. T., & Kalliomäki, M. (2021) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2021-003293 · Cited by 12
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
Bossi, P., Escobar, Y., & Pea, F. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.893530 · Cited by 18
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors
Bianco, G. L., Lanza, E., Provenzano, S., Federico, M., Papa, A., Imani, F., Shirkhany, G., Laudicella, R., & Quartuccio, N. (2022) · Anesthesiology and Pain Medicine · doi:10.5812/aapm-126333 · Cited by 15
“Based on the European Society for Medical Oncology guidelines, spine surgery is indicated only in the case of malignant spinal cord compression (SCC) (56).”
BackgroundShkodra, M., Brunelli, C., Zecca, E., Infante, G., Miceli, R., Caputo, M., Bracchi, P., Dico, S. L., Kaasa, S., & Caraceni, A. T. (2022) · Palliative Medicine · doi:10.1177/02692163221122354 · Cited by 14
Donati, C. M., Nardi, E., Zamagni, A., SIEPE, G., Mammini, F., Cellini, F., Rito, A. D., Portaluri, M. G. A., Tommaso, C. D., Santacaterina, A., et al. (2022) · Cancers · doi:10.3390/cancers14194660 · Cited by 13
Gabapentinoid Prescribing Practices at a Large Academic Medical Center
Huang, L. L., Wright, J. A., Fischer, K. M., Croghan, I. T., Nanda, S., Schroeder, D. R., & Vincent, A. (2023) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.12.002 · Cited by 14
“Table 3 summarizes the level of evidence supporting (or not supporting) the indications for gabapentinoid prescriptions in the overall cohort.(14-54) Gabapentinoid prescriptions for pain-related indications, such as neuropathic pain, headaches, and musculoskeletal pain, were the most common (82.”
BackgroundBilmiç, E., Selçukbırıcık, F., & Bağçıvan, G. (2023) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2023.102422 · Cited by 12
Opioid Use and Gut Dysbiosis in Cancer Pain Patients
Coluzzi, F., Scerpa, M. S., Loffredo, C., Borro, M., Pergolizzi, J. V., LeQuang, J. A., Alessandri, E., Simmaco, M., & Rocco, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147999 · Cited by 16
“Opioids are still a cornerstone in the management of severe chronic pain, particularly in cancer patients [1].”
BackgroundOpioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline
Davis, M. P., Davies, A. N., McPherson, M. L., Reddy, A. S., Paice, J. A., Roeland, E. J., Walsh, D., Mercadante, S., Case, A. A., Arnold, R. M., et al. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09286-z · Cited by 23
“A reasonable starting dose is 10–15% of the MEDD [77].”
Self-citationHow I treat pain in hematologic malignancies safely with opioid therapy
Geyer, H. L., Gazelka, H. M., & Mesa, R. A. (2020) · Blood · doi:10.1182/blood.2019003116 · Cited by 14
Xu, Y., Cuthbert, C. A., Karim, S., Kong, S., Dort, J. C., Quan, M. L., Hinther, A. V., Quan, H., Hemmelgarn, B. R., & Cheung, W. Y. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003938 · Cited by 12
Cryoneurolysis in Patients with Dorsal Neuropathic Pain Secondary to Tumor Invasion
Daubié, S., Pilleul, F., Thivolet, A., Kalenderian, A.-C., Cuinet, M., Ricoeur, A., Schiffler, C., Bouhamama, A., Chvetzoff, G., & Mastier, C. (2020) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2020.01.018 · Cited by 12
Opioid safety recommendations in adult palliative medicine: a North American Delphi expert consensus
Lau, J., Mazzotta, P., Whelan, C., Abdelaal, M., Clarke, H. A., Furlan, A. D., Smith, A., Husain, A. F., Fainsinger, R. L., Hui, D., et al. (2021) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2021-003178 · Cited by 18
Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke
Peyravian, N., Sun, E., Dikici, E., Deo, S. K., Daunert, S., & Toborek, M. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00079 · Cited by 14
Han, B.-J., Liu, Y., Jin, J.-Y., Xu, H.-K., Zhang, W., Ren, S., Wang, X. S., & Liu, J. (2023) · World Journal of Traditional Chinese Medicine · doi:10.4103/2311-8571.382112 · Cited by 14
Lau, J., Flamer, D., & Murphy-Kane, P. (2019) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-019-01482-w · Cited by 16
The role of methadone in cancer-induced bone pain: a retrospective cohort study
Sulistio, M., Wojnar, R., Key, S., Kwok, J., Al-Rubaie, Z. T., & Michael, N. G. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05606-7 · Cited by 12
Sumitani, M., Nishizawa, D., Hozumi, J., & Ikeda, K. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24756 · Cited by 12
Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group
Rational Use of Analgesics (RUA) Group, Varrassi, G., Coluzzi, F., Guardamagna, V. A., Puntillo, F., Sotgiu, G., & Vellucci, R. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00248-x · Cited by 12
“Although the oral route of administration of analgesic drugs should be advocated as the first choice [11], transdermal, transmucosal, and intranasal routes can be considered in patients with cancer who may have several contraindications to oral administration such as nausea, vomiting, problems with swallowing (dysphag…”
BackgroundResultInfluentialDavies, A. N., Cinieri, S., Dupoiron, D., España, S., Leclerc, J., Montesarchio, V., Mystakidou, K., Serna, J., Tack, J. F., & on behalf of the NACASY Study Group (2022) · Cancers · doi:10.3390/cancers14051128 · Cited by 12
(2013) · Clinical Pharmacokinetics · doi:10.1007/40262.1179-1926 · Cited by 12
Duan, J., Fang, W., Xu, H., Wang, J., Chen, Y., Ding, Y., Dong, X., Fan, Y., Gao, B., Hu, J., et al. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.08.004 · Cited by 20
Lü, F., Wang, X., Tian, J., & Li, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1292758 · Cited by 11
Dupoiron, D., Bienfait, F., Carvajal, G., Seegers, V., Douillard, T., Jubier-Hamon, S., Delorme, T., Julienne, A., Pluchon, Y. M., Ribault, N., et al. (2023) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2023-104961 · Cited by 11
“Due to the retrospective nature of the study and considering that it involves an approved treatment, 21 22 the requirement for written informed consent was waived (online supplemental file 1).”
BackgroundMethadone in Cancer-Related Neuropathic Pain: A Narrative Review
Ragaban, F., Purohit, O. P., & Fabbro, E. D. (2024) · Current Oncology · doi:10.3390/curroncol31120561 · Cited by 11
“The European Society for Medical Oncology (ESMO) provides recommendations for CRNP, including “opioid combination therapies and carefully dosed adjuvants, when opioids alone provide insufficient pain relief” [4].”
Bohren, Y., Cachemaille, M., Timbolschi, D. I., & Perruchoud, C. (2025) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03920-9 · Cited by 17
“For example, interventional treatments for neuropathic pain are based on weak evidence and are not proposed to patients with neuropathic cancer pain [43].”
Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Romero-Morelos, P., Ruvalcaba-Paredes, E. K., Garciadiego-Cázares, D., Pérez-Santos, M., Reyes-Long, S., Alfaro-Rodríguez, A., Salcedo, M., Mancilla-Ramírez, J., & Bandala, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666201111112748 · Cited by 12
Dzierżanowski, T., & Kozlowski, M. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-139152 · Cited by 11
Cancer pain during an epidemic and a pandemic
Paice, J. A. (2022) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000594 · Cited by 16
Løhre, E. T., Svedahl, A., Jakobsen, G., Solheim, T. S., Klepstad, P., & Thronæs, M. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00485-2 · Cited by 13
“For compliance with common palliative care prescription standards, the doses were described as milligrams per 24 h [3, 25].”
BackgroundDing, H., Zheng, X., Kong, S., Gong, L., Ding, Q., & Huang, P. C. (2020) · European Journal of Cancer Care · doi:10.1111/ecc.13225 · Cited by 11
Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient
Pham, M. N., Hudnall, M. T., & Nadler, R. B. (2020) · Urology · doi:10.1016/j.urology.2020.01.029 · Cited by 21
Vuattoux, D., Colomer‐Lahiguera, S., Fernandez, P.-A., Gygax, M. J., Choucair, M., Popovic, M. B., Diezi, M., Manificat, S., Latifyan, S., Ramelet, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.595734 · Cited by 18
Sørensen, J., Sjøgren, P., Clemmensen, S. N., Sørensen, T. V., Heinecke, K., Larsen, H., Eidemak, I., & Kurita, G. P. (2022) · Scandinavian Journal of Pain · doi:10.1515/sjpain-2021-0162 · Cited by 13
Multidisciplinary Approach to Cancer Pain Management.
Kettyle, G. (2023) · PubMed Central · Cited by 10
Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update
Formenti, P., Umbrello, M., Pignataro, M., Sabbatini, G., Dottorini, L., Gotti, M., Brenna, G., Menozzi, A., Terranova, G., Galimberti, A., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14050483 · Cited by 11
“This is an approach in which various analgesics are combined to maximize pain relief while simultaneously minimizing their adverse effects [65].”
BackgroundShifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis
Imkamp, M. S. V., Theunissen, M., Viechtbauer, W., van Kuijk, S. M. J., & Everdingen, M. H. J. V. D. B.-V. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.05.022 · Cited by 10
Ragusa, C., Pereira, B., & Balayssac, D. (2024) · International Journal of Cancer · doi:10.1002/ijc.35280 · Cited by 11
“6,13 Our analysis of pain characteristics showed that the prevalence rates for chronic pain and neuropathic pain (92.34% and 67.2% of participants with pain, respectively) were much higher than those reported in the 2010 INCa survey (56% and 43% of the outpatients with pain had chronic pain or…”
InfluentialCancer Pain Is Not One-Size-Fits-All: Evolving from Tradition to Precision
Shapoo, N., Rehman, A., Rojas, C. A. I., Gotlieb, V. K., & Boma, N. (2025) · Clinics and Practice · doi:10.3390/clinpract15100173 · Cited by 14
Cancer Pain Management: An Italian Delphi Survey from the Rational Use of Analgesics (RUA) Group
Varrassi, G., Conno, F. D., Orsi, L., Puntillo, F., Sotgiu, G., Zeppetella, J., & Zucco, F. (2020) · Journal of Pain Research · doi:10.2147/jpr.s243222 · Cited by 10
Tuca, A., Viejo, M. Á. N., Maradey, P., Canal-Sotelo, J., Mancilla, P. G., Rivero, S. G., Casillas, I. R., Abián, M. H., & Bermudo, C. L. (2022) · Future Oncology · doi:10.2217/fon-2021-1639 · Cited by 11
Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies
Ruppert, L. M., Dayan, E. S., Keegan, N. M., Bacharach, A., Woo, S., Gillis, T. A., & Scher, H. I. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00816 · Cited by 10
“Rarely considered, however, is that referenced guidelines here are specific to cancer-related pain only.(30,31) Beyond applying spinal neurorehabilitation to malignant spinal cord compromise, the recommendations of dedicated physiatrists can add significantly to patient management by identifying and tailoring therapeu…”
BackgroundSonohata, M., Wada, S., Koretaka, Y., Morioka, Y., Mishima, H., & Mawatari, M. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00392-y · Cited by 10
Batistaki, C. Z., Graczyk, M., Janecki, M., Lewandowska, A. A., Moutinho, R., & Vagdatli, K. (2022) · Drugs in Context · doi:10.7573/dic.2022-9-4 · Cited by 10
Opioid Prescription Denials by Community Pharmacies for Cancer-Related Pain: A Case Series
Heung, Y. J., Clark, M. D., Tschanz, J., & Bruera, E. D. (2023) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2023.06.027 · Cited by 10
Challenges and Opportunities in Developing Tailored Pain Management Strategies for Liver Patients
Majid, M., Yahya, M., Owusu, F. A., Bano, S., Tariq, T., Habib, I., Kumar, B., Kashif, M., Varrassi, G., Khatri, M., et al. (2023) · Cureus · doi:10.7759/cureus.50633 · Cited by 20
“Chronic pain not only compromises the patient's ability to perform daily activities but also contributes to mental health challenges, including anxiety and depression [2].”
BackgroundPiotrowska, W., Leppert, W., & Majkowicz, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s179012 · Cited by 10
Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
Albiach, C. F., Estévez, F. V., Alarcón, M. D. L., de Madariaga, M., Carregal, A., Arranz, J., Martín-Arroyo, J. M. T., López, A. J. J., & Sanz-Yagüe, A. (2019) · Journal of Pain Research · doi:10.2147/jpr.s194881 · Cited by 10
“In particular, current ESMO guidelines recommend a single 8 Gy dose of external beam radiotherapy in association with analgesics for patients with painful bone metastases (level of evidence I, degree of recommendation A).(14)”
Backgroundde Lucas, R. H., Fernández, M. N., Gómez-Caamaño, A., López, R. M., de la Torre, I. F., la Torre Tomás, A. D., Muñoz-Garzón, V., Bermudo, C. L., & Rueda, A. M. (2021) · Future Oncology · doi:10.2217/fon-2020-1063 · Cited by 10
Quality of End-of-Life in Cancer Patients With Dementia: Using A Nationwide Inpatient Database
Hirooka, K., Okumura, Y., Matsumoto, S., Fukahori, H., & Ogawa, A. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.03.016 · Cited by 12
Fan, R., Li, X., Yang, S., Bu, X., Chen, Y., Wang, Y., & Qiu, C. (2022) · Pain Research and Management · doi:10.1155/2022/8943292 · Cited by 10
“In addition to self-assessment pain, observation of pain-related behaviors and discomfort (like facial expression, body movements, changes in interpersonal interactions, and routine activity) are alternative strategies for assessing the presence of pain [40].”
MethodBao, Y., Zhang, H., Hartung, D. M., Witkin, L. R., & Paice, J. A. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00867 · Cited by 10
“For this population, international consensus supports the use of opioids for moderate-to-severe pain associated with cancer and its treatment.(2) Adding to the concerns are recent studies revealing 20%-40% declines in opioid prescriptions dispensed to patients with cancer with poor prognosis and near the end of life(3…”
BackgroundPsychometric Evaluation of the Nurses' Cancer Pain Management Competency Scale
Hu, J. Y., & Roh, Y. S. (2022) · Pain Management Nursing · doi:10.1016/j.pmn.2022.08.009 · Cited by 9
Robinson, O. C., Pini, S. A., Flemming, K., Campling, N. C., Fallon, M., Richards, S. H., Mayland, C. R., Boland, E. G., Swinson, D., Hurlow, A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-078619 · Cited by 11
“However, this study and previous research has highlighted that patients can often be reluctant to express their concerns and preferences without prompting.”
BackgroundInfluentialSelf-citationHan, H.-Z., Li, B., Yang, R., Guo, H., Li, Q., Wang, H., Zheng, B., Bai, Y., & Yu, Y. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00733 · Cited by 11
Beng, T. S., Chai, C.-S., Ng, D.-L.-C., Zainuddin, S. I., Capelle, D. P., Lam, C. L., Ang, C. M., Chai, W. L., Ishak, N. N. N., Ong, Y. X., et al. (2024) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2023-004762 · Cited by 12
Zhang, L., Luo, Y., Mao, D., Zhu, B., Yang, Z., Miao, J., & Zhang, L. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151727 · Cited by 10
Gauchez, L., Boyle, S. L. L., Eekman, S. S., Harnie, S., Decoster, L., Ginderdeuren, F. V., Nys, L. D., & Adriaenssens, N. (2024) · Cancers · doi:10.3390/cancers16193371 · Cited by 11
Davies, A. N., Fagan, N., González‐Barboteo, J., Chelazzi, C., Economos, G. P. S., Elsner, F., Leach, C., Monsen, R. E., Oldenmenger, W. H., Rémi, C., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08898-1 · Cited by 9
“Cancer pain guidelines universally recommend the co-prescription of “laxatives” with opioid analgesics [13, 14], although previous research suggests that this practice is not universal [15, 26].”
Use of Essential Medicines for Pain Relief and Palliative Care: A Global Consensus Process
Pastrana, T., Lima, L. D., Dudgeon, D. J., Voeuk, A., Ahmed, E., & Radbruch, L. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.10.024 · Cited by 9
Ten‐year analgesic utilization patterns and economic implications in Portugal
Duarte, N., Martins, J. P., García‐Pedraza, J. Á., & Santos, M. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16333 · Cited by 11
“6 Although opioids are unquestionably valuable in managing cancer pain, 7 the benefit provided in non-cancerous chronic pain of different origins is considered small, with increased risk of adverse drug reactions and less pain relief in long periods of treatment due to tolerance development.”
Opioid Use in Cancer Pain Management: Navigating the Line Between Relief and Addiction
Trullols, M., & de Porras, V. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157459 · Cited by 15
“According to the WHO and the European Association for Palliative Care, morphine is the opioid of choice for the treatment of moderate to severe CRP, particularly in settings where close monitoring and titration are feasible [54].”
InfluentialCan Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
Ostan, R., Gambino, G., Malavasi, I., Ronga, G., Solipaca, M., Spunghi, M., Varani, S., Pannuti, R., & Ruggeri, E. (2021) · Cancers · doi:10.3390/cancers13225736 · Cited by 9
LncRNA NONRATT009773.2 promotes bone cancer pain progression through the miR‐708‐5p/CXCL13 axis
Chen, J., Lu, C., Wang, X., Wang, L., Chen, J., & Ji, F. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15607 · Cited by 9
“About 75% of patients with advanced cancer undergo moderate to severe BCP (Fallon et al., 2018).”
BackgroundLucarini, E., Micheli, L., Rajagopalan, R., Ciampi, C., Branca, J. J. V., Pacini, A., Leandri, M., Rajagopalan, P., Ghelardini, C., & Mannelli, L. D. C. (2023) · Pain · doi:10.1097/j.pain.0000000000002963 · Cited by 10
“32 Paclitaxel leads to both macrophage infiltration in the dorsal root ganglia (DRG) and is responsible for microglia or astrocyte activation in the spinal cord 71 which cause a prolonged activity in dorsal horn neurons.”
BackgroundCuménal, M., Lamoine, S., Méleine, M., Aissouni, Y., Prival, L., Fereyrolles, M., Barbier, J., Cercy, C., Boudieu, L., Schopp, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116887 · Cited by 10
Pointreau, Y., Bensadoun, R., Béra, G., Sire, C., Ruffier, A., Janoray, G., Calais, G., Bollet, M. A., Pinel, B., Braniste, V., et al. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s246757 · Cited by 9
Laser-photobiomodulation on experimental cancer pain model in Walker Tumor-256
Petrellis, M. C., da Fonseca, G. A. M. D., Pinto, A. D. B., Rosa, F. O., Maria, D. A., Shibli, J. A., & Frigo, L. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111979 · Cited by 9
Qin, W., Yang, Y., Zhang, L., Yang, Q., Li, P., & Fan, B. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.12.012 · Cited by 10
Al‐Ansari, A. M., Abd‐El‐Gawad, W. M., AboSerea, S. M., ElShereafy, E. E. S., Ali, F. A. S., & ElSayed, M. A. E. (2021) · BMC Palliative Care · doi:10.1186/s12904-021-00717-2 · Cited by 9
Santis, S. D., Simone, M. D., Mercadante, S., Mediati, R. D., Vellucci, R., Marchetti, P., Tonini, G., Cuomo, A., Caraceni, A. T., Natoli, S., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s290551 · Cited by 9
“More recently, other parameters (eg, pain type, other treatments, co-morbidities) have been suggested to be considered in the therapy choice process.(2,4) Indeed, it was suggested that the unsuccessful analgesia was depending on the complexity of cancer pain and clinical characteristics, and that therapeutic managemen…”
BackgroundBienfait, F., Jubier-Hamon, S., Seegers, V., Pluchon, Y., Lebrec, N., Jaoul, V., Boré, F., Delorme, T., Robert, J., Bellanger, M. M., et al. (2021) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13469 · Cited by 9
Treillet, E., Giet, O., Picard, S., Laurent, S., & Serresse, L. (2021) · Journal of Palliative Medicine · doi:10.1089/jpm.2021.0309 · Cited by 9
“In 12–14 The regulatory authorities in France (The National Agency for the Safety of Medicines and Health Products and the French National Authority for Health) do not propose a specific protocol, 11,15 leaving the decision making to individual practitioners.”
de Barros, G. A. M., Baradelli, R., Rodrigues, D. G., Toffoletto, O., Domingues, F. S., Gayoso, M., Lopes, A., Afiune, J. B., & Guimarães, G. M. N. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000979 · Cited by 10
“ual variations with unpredictable occurrence of side effects, and incomplete cross tolerance with other m opioids.(1,13,17,28) Methadone usage has not achieved a consensus even in chronic noncancer pain.”
BackgroundInfluentialZiconotide for the Management of Cancer Pain: A Budget Impact Analysis
Lambe, T., Duarte, R. V., Eldabe, R., Copley, S., Kansal, A., Black, S. R., Dupoiron, D., & Eldabe, S. S. (2022) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2022.08.458 · Cited by 11
Dupoiron, D., Brill, S., Eeltink, C., Barragán, B., Bell, D., Petersen, G., Eerdekens, M., Ryan, D., & Rakuša, M. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13728 · Cited by 12
“However, CRNP is likely to be under-recognised and under-treated in clinical practice (Edwards et al., 2019; Fallon et al., 2018).”
BackgroundInfluentialSazuka, S., & Koitabashi, T. (2020) · Journal of Anesthesia · doi:10.1007/s00540-020-02821-8 · Cited by 14
Irelli, A., Ranieri, J., Sirufo, M. M., Pietro, F. D., Casalena, P., Ginaldi, L., Cannita, K., & Giacomo, D. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082144 · Cited by 11
Transdermal Patches Containing Opioids in the Treatment of Patients with Chronic Pain
Marco, I. D. (2023) · Processes · doi:10.3390/pr11092673 · Cited by 8
Afessa, N., Birhanu, D., Negese, B., & Tefera, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294230 · Cited by 8
Morais, M. V., Lopes, R. A., & de Oliveira, J. O. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108571 · Cited by 8
Hao, J., He, Z., Li, Y., Huang, B., Remis, A., Yao, Z., & Zhu, D. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08813-8 · Cited by 13
“Current clinical practice guidelines for cancer pain mainly focus on opioids and non-opioid analgesics [38].”
Jovanovic, D., Krstić, V. Ć., Kabalak, P. A., Viola, L., & Papatheodosiou, K. (2024) · Breathe · doi:10.1183/20734735.0203-2023 · Cited by 11
“…in a patient who has relatively stable and adequately controlled basic pain), pain syndrome, pain at rest and/or while moving, presence of trigger or relieving factors, psychosocial factors, detailed medical history and precise data on use of analgesics and their efficacy and tolerability [19, 20].”
InfluentialMyint, O. W., Yoong, S. Q., Toh, E., Lei, F., & Jiang, Y. (2024) · Journal of Clinical Nursing · doi:10.1111/jocn.17547 · Cited by 20
Wang, K., Zhang, Y., Shu, R., Yuan, L., Tu, H., Wang, S., Ni, B., Zhang, Y., Jiang, C., Luo, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202417367 · Cited by 8
Chukwusa, E., Law-Clucas, S., Gulliford, M. C., Bajwah, S., Barclay, S. I. G., Kumar, R. K., Clarke, G., Siriwimala, T., & Koffman, J. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03200-4 · Cited by 10
Gaetano, F. D., Totaro, N., & Ventura, C. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111626 · Cited by 11
Wu, T., Hsu, C., Sun, W., Chen, H., Lin, C., & Shao, Y. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100255 · Cited by 8
Wang, J.-H., Wang, L.-W., Liang, S., Rosenberg, J. P., Wang, T.-J. T., Wu, S. V., & Liu, C. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06722-8 · Cited by 8
Atrux‐Tallau, N., Naimi, Z., & JAUDINOT, E. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01214-x · Cited by 8
“The WHO [1], the European Society for Medical Oncology (ESMO) [8], the Centers for Disease Control and Prevention (CDC) [9] and the American Geriatrics Society [10] have made the following general recommendations for the prescription of opioids in pediatric, adult, and elderly populations: use of the least invasive ro…”
BackgroundGravdahl, E., Steine, S., Augestad, K. M., & Fredheim, O. M. S. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08045-2 · Cited by 8
“Guidelines for symptom treatment in palliative care are based on the subcutaneous route [1, 2, 12] but advocate the intravenous route when subcutaneous administration is likely to fail, rapid pain control is needed or the patient already has a central venous catheter (CVC).”
BackgroundNasir, K. S., Hafeez, H., Jamshed, A., & Hussain, R. (2020) · Journal of Cancer & Allied Specialties · doi:10.37029/jcas.v6i2.367 · Cited by 8
“Before treatment with a nerve block, all participants received at least three concurrent classes of medications, consisting of an opioid analgesic, either a tricyclic antidepressant or gabapentinoids (gabapentin or pregabalin) and either paracetamol or non-steroidal anti-inflammatory medication for the management of H…”
MethodShi, C., Liu, J., Hu, J., Chen, X., Xie, J., Luo, J., Wang, C., Wang, H., Yuan, Q. X., Zhu, H., et al. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00353-5 · Cited by 9
Jung, J. Y., Chon, H. J., Choi, Y. J., Yeon, S.-E., Choi, S. Y., & Lee, K. H. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06992-w · Cited by 11
Patients’ Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study
Mazzotta, M., Filetti, M., Piras, M., Mercadante, S., Marchetti, P., & Giusti, R. (2022) · Cancer Management and Research · doi:10.2147/cmar.s353036 · Cited by 8
“Moreover, we also previously demonstrate that level of satisfaction was significantly associated with the use of fastest onset opioids, especially fentanyl pectin nasal spray (FPNS).(2,6,7,9) The last point is represented by the interference of BTcP with Activities of daily living (ADLs).”
BackgroundSelf-citationUehara, Y., Matsumoto, Y., Kosugi, T., Sone, M., Nakamura, N., Mizushima, A., Miyashita, M., Morita, T., Yamaguchi, T., & Satomi, E. (2022) · BMC Palliative Care · doi:10.1186/s12904-022-01056-6 · Cited by 8
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Breder, V. V., Маркович, Б. Ю., Vladimirova, L. Y., Volkov, N., Ергнян, С. М., Zhabina, A. S., Kononets, P. V., et al. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.3.201848 · Cited by 12
Wu, S., Jin, T., Ma, B., Ji, Y. S., Huang, X., Wang, P., Liu, X., Владимирович, К. Б., Liu, X., & Ma, K. (2023) · Cancer Medicine · doi:10.1002/cam4.4922 · Cited by 8
Metadata
- Authors
- Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I.
- Affiliations
- Edinburgh Cancer Research (GB)
- Azienda Ospedaliera Sant'Andrea (IT)
- University of L'Aquila (IT)
- Mount Vernon Cancer Centre (GB)
- RWTH Aachen University (DE)
- Walton Centre (GB)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Issue
- Suppl 4
- Pages
- iv166-iv191
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2834719472
- Cited by
- 954
- References
- 184
- Citations by year
- 2026: 136 · 2025: 140 · 2024: 143 · 2023: 123 · 2022: 129 · 2021: 126 · 2020: 88 · 2019: 61 · 2018: 6
- FWCI
- 103.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 463 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Marie Curie (MCCC-RP-12-A14197, MCCC-RP-15-A18862, MCCC-RP-15-A19005)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pediatric Pain Management Techniques
- Keywords
- cancer pain, pain management, advanced cancer, metastatic cancer, terminal cancer, pain prevalence, palliative care, analgesia
- MeSH terms
- Cancer Pain, Cancer Survivors, Pain, Procedural, Procedural Pain, Adult, Analgesics, Opioid, Antineoplastic Combined Chemotherapy Protocols, Europe, Humans, Medical Oncology, Neoplasm Staging, Neoplasms, Pain Measurement, Societies, Medical, Terminal Care, Prevalence, Treatment Outcome, Breakthrough Pain, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.